ELI LILLY AS A POSSIBLE GAMECHANGER IN THE HEALTHCARE SECTOR
-Eli Lilly $LLY+1.8% is currently the most valuable healthcare company in the world, valued at around $550 billion.
- The company's stock has been one of the most sought-after in the healthcare sector.
- Despite the high value, there are many growth opportunities for Eli Lilly in the pharmaceutical industry.
- Donanemab is a promising drug in the pipeline, targeting early Alzheimer's disease.
- Clinical trials have demonstrated its effectiveness in slowing cognitive decline, with 29% efficacy compared to another approved product.
- Donanemab has potential benefits with FDA approval.
- Compared to another drug, Biogen's Leqembi, it achieves potentially better results.
- Eli Lilly estimates a decision early this year 2024.
High earnings potential, Progressive development of a cure for Alzheimer's disease, a sought after stock in the healthcare industry, would you consider investing in such a company?
If one looks at the chart from a long-term perspective, one finds that the company has never sold off properly except in 2000 and is still rising. That's great for stock owners, but for new investors given the valuation, I think it's high. But on the stock, that doesn't mean the growth is over. The company can continue to strengthen. I don't own it and I'm not thinking about buying it at this time.